Molecular Imaging and Radionuclide Therapy | 2021

A Case with 68Ga-FAPI Positive and 18F-FDG Negative Breast Cancer

 
 
 
 

Abstract


A female patient diagnosed of infiltrative breast carcinoma using tru-cut biopsy underwent 18flourine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for staging. The tumor was located in the superior external quadrant of the right breast, and did not exhibit pathological uptake in 18F-FDG PET/CT. Later, gallium-68 (68Ga) fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT imaging was performed and the primary tumor showed intense radiotracer accumulation. This presumes that 68Ga-FAPI PET/CT imaging is superior to 18F-FDG imaging in detecting the primary tumor in breast cancer, thereby suggesting the replacement of FAPI by 18F-FDG in breast-cancer staging in the future.

Volume 30
Pages 201 - 204
DOI 10.4274/mirt.galenos.2021.69926
Language English
Journal Molecular Imaging and Radionuclide Therapy

Full Text